 |
|
| With increasing pricing pressures in a therapeutic area which has seen many recent drug approvals, diabetes drug developers are seeking to enhance their clinical development and portfolio. By leveraging Continuous Glucose Monitoring (CGM), sponsors conducting trails in diabetes as well as other indications have the potential to enhance patient safety, accelerate clinical development and increase commercial value. |
|
| Attend this live webinar to hear QuintilesIMS, in collaboration with key CGM opinion leaders, discuss the advantages of using CGM in your clinical trials. |
|
| Register for this webinar to learn: |
|
• |
|
Expert insights from QuintilesIMS's Diabetes Center of Excellence |
|
|
• |
|
Firsthand case studies on how using CGM devices can help increase commercial value |
|
|
• |
|
Opportunities for CGM to accelerate clinical trials |
|
|
|
|
|
|
|
| Presenters: |
|
Erica Caveney, MD
Vice President, Global Head, Diabetes Center of Excellence, QuintilesIMS |
|
James R. Johnson, PhD
Principle Biostatistician and Pharmacokineticist, Summit Analytical |
|
Poul Strange, MD, PhD
Founder, President and Medical Director, Integrated Medical Development, LLC |
|
| Moderator: |
|
Michelle Maskaly
Senior Editor, Applied Clinical Trials |
|
|
|
|
|
For technical questions about this webinar,
please contact Kristen Moore at kristen.moore@ubm.com |
|
|
|
| |
|
Contact us at
www.quintilesims.com
|
|
|
|
|
|
